DOCSLIB.ORG

Medicines Considered for Classification at the Seventh Meeting of the Medicines Classification Committee Held on 31 July And

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Medicines Considered for Classification at the Seventh Meeting of the Medicines Classification Committee Held on 31 July And • MEDICINES CONSIDERED FOR CLASSIFICATION AT THE SEVENTH MEETING OF THE MEDICINES CLASSIFICATION COMMITTEE HELD ON 31 JULY AND 1 AUGUST 1990 - Page 2 - EXTERNAL CURRENT PROPOSED MCC BNF l MEDICINE USE (X) CLASSIFICATION CLASSIFICATION RECOMMENDATION 6. l Acarbose New PM Prescription Only 2 .4 Acebutolol; and its salts PM PM Prescription Only 4.7 Acetanilide; and alkyl acetanilides; in medicines containing more than 0.5% of acetanilide 5.4 Acetarsol; and its salts 11. 7 Acetazolarnide; and its salts 13. 7 Acetic acid, glacial; in medicines for external use 6. I Acetohexamide 9.6 Acetomenaphthone x-ray Acetrizoate sodium 4. I Acetylcarbromal 11. 8 Acetylcholine; and its salts 3. 7 Acetylcysteine; and its salts 2. I Acetyldigitoxin 2. I Acetylstrophanthidin - Page 3 - EXTERNAL CURRENT PROPOSED MCC BNF NO MEDICINE USE (X) CLASSIFICATION CLASSIFICATION RECOMMENDATION 5.3 Aciclovir, in medicines for external use, except in medicines for ophthalmological use x PM PTOM Part I Pharmacy 5.3 Aciclovir; and its salts; in medicines for internal use and ophthalmological use PM PTOM Prescription Only 2. 12 Acipimox PM Prescription Only 13. 6 Acitretin New PM Prescription Only 10.3 Aconite; alkaloids of; and their salts; in medici~es for external use containing less than 0.02% of the alkaloids of aconite x POM Obsolete General 13. 11 Acrif lavine, in medicines for external use x POM PTOM Part II Pharmacy 8. 1 Act:inomycin D PM PM Prescription Only 1.2 Adiphenine; and its salts RM Obsolete Obsolete 13. 4 Adrenal Extract, in dermatological medicines containing more than 0.02% of Ketosteroids x PM PM Prescription Only 13.4 Adrenal extract, in dermatological mediciries containing 0.02% or less of ketosteroids x POM G General 2.7 Adrenaline; and its salts POM PTOM Part II Pharmacy - Page 4 - '-.... _ EXTERNAL CURRENT PROPOSED MCC BNF NO MEDICINE USE (X) CLASSIFICATION CLASSIFICATION RECOMMENDATION 13. 14 Aescin, in medicines for external use x POM G General 5.5 Albendazole PM 9.2 Albumin, human PM PM Prescription Only 10. 1 Alclofenac PM PM Prescription Only 13.4 Alclometasone; and its esters x PM PM Prescription Only 13. 11 Alcohol, absolute; in medicines for internal and external use x POM PTOM Part I Pharmacy 13. 11 Alcohol, isopropyl; in uncompounded medicines for external use x POM G Part II Pharmacy 15. 1 Alcuronium; and its salts PM PM Prescription Only 6.7 Aldosterone PM PM Prescription Only 9.6 Alfacalcidol PM PM Prescription Only 3.4 Allergens PM PM Prescription Only 10. 1 Allopurinol PM PM Prescription Only 6. 4 Allyloestrenol PM PM Prescription Only 1. 6 Aloes; in medicines for internal use POM G Part II Pharmacy - Page 5 - EXTERNAL CURRENT PROPOSED MCC BNF NO MEDICINE USE (X) CLASSIFICATION CLASSIFICATION RECOMMENDATION 1. 6 Aloes; in medicines for external use x General 1. 6 Aloin POM PTOM 4.7 Aloxiprin POM PTOM Part II Pharmacy 15. 1 Alphadolone; and its esters PM PM Prescription Only 15. 1 Alphaxalone PM PM Prescription Only 4. 1 Alprazolam PM PM Prescription Only 2. 4 Alprenolol; and its salts PM PM Prescription Only 2.5 Alseroxylon PM PM Obsolete 13. 11/ Aluminium and its sa 1 ts; in 13. 12 medicines for external use x POM G General 4.9 Amantadine; and its salts PM PM PI'escription Only 1. 2 Ambutonium; and its salts RM Obsolete Obsolete .. 13.4 Amcinonide x PM PM Prescription Only 11. 7 Amethocaine; and its salts; in medicines for internal and ophthalmological use PM PM Prescription Only 15.2 Amethocaine; and its salts; in medicines for external use excluding ophthalmological use x Part II Pharmacy - Page 6 - EXTERNAL CURRENT PROPOSED MCC BNF NO MEDICINE USE (X) CLASSIFICATION CLASSIFICATION RECOMMENDATION 4.7 Amidopyrine; and its salts and esters PM PM Prescription Only x-ray Amidotrizoic acid; and its salts RM PM Prescription Only 5. 1 Amikacin; and its salts PM PM Prescription Only ,;;..· 2.2 Amiloride; and its salts PM PM Prescription Only 13. 11 Aminacrine; and its salts; in medicines for ext:ernal use x PM/POM PTOM Part I Pharmacy 2.11 Aminocaproic acid; and its salts and esters PM PM Prescription Only 8.3 Aminoglutethimide PM PM Prescription Only 2.2 Aminometradine PM PM Prescription Only 3. 1 Aminophylline; except in liquid form for oral use POM PM Prescription Only 4.5 Aminorex; and its salts PM PM Prescription Only 1. 5 Aminosalicylic acids; and their salts and esters PM PM Prescription Only 2.3 Amiodarone; and its salts PM PM Prescription Only 3.5 Amiphenazole; and its salts PM PM Prescription Only 2.2 Amisometradine PM PM Obsolete - Page 7 - EXTERNAL CURRENT PROPOSED MCC BNF NO MEDICINE USE (X) CLASSIFICATION CLASSIFICATION RECOMMENDATION 4.3 Amitriptyline; and its salts PM PM Prescription Only 2.6 Amlodipine besylate New Prescription Only 5.4 Amodiaquine; and its salts PM PM Prescription Only 4.3 Amoxapine; and its salts PM PM Prescription Only 5. 1 Amoxycillin; and its salts PM PM Prescription Only 5.2 Amphotericin x PM PM Prescription Only 5. 1 Ampicillin; and its salts PM PM Prescription Only 2. 1 Amrinone PM PM Prescription Only 8. 1 Amsacrine PM Prescription Only 2.5 Amyl nitrite POM PTOM Part I PhaI"macy 13.8 Amyldimethylamino benzoate; in medicines for external use x POM G Obsolete 6.4 Anabolic hormones Prescription Only 15.2 Anaesthetics 1 local; in medicines for parenteral use and internal use by ingestion, other than throat lozenges; and except when sold to a dental nurse PM PM Prescription Only - Page 8 - EXTERNAL CURRENT PROPOSED MCC BNF NO MEDICINE USE (X) CLASSIFICATION CLASSIFICATION RECOMMENDATION 15.2 Anaesthetics, local; in medicines for ophthalmic use, except when sold to a registered optometrist for the purpose of use in his practice as an optometrist PM PM Prescription Only 15.2 Anaesthetics,local; except those specified elsewhere in this schedule, and except in medicines for external use containing 2% or less of any local anaesthetic POM PTOM Part II Pharmacy 15.2 Anaesthetics, local; in medicines which are throat lozenges General 2.8 Ancrod; and its immunoglobulin antidote PM PM Prescription Only 6.4 Androgens, either natural or synthetic; and their derivatives PM PM Prescription Only 2. 10 Anistreplase New Prescription Only 1. 1 Antacids, unless specified elsewhere in the schedule G General 11. 4 Antazoline;' and its salts, when used externally; and except when sold at an airport x POM G Part II Pharmacy 5.5 Anthelmintics, except those specified elsewhere in this schedule POM PTOM Part II Pharmacy - Page 9 - EXTERNAL CURRENT PROPOSED MCC BNF NO MEDICINE USE (X) CLASSIFICATION CLASSIFICATION RECOMMENDATION 6.4 Anti androgens Prescription Only 2.3 Anti-arrhythmics Prescription Only 6. 1 Anti-diabetic medicines for oral use PM PM Prescription Only 9.0 Anti-haemophilic factor (human) Prescription Only 8.2 Anti-human lymphocyte globulin PM PM Prescription Only 1. 2 Anticholinergic medicines not specified elsewhe're in this schedule RM PTOM Part I Pharmacy 2.8 Anticoagulants; except heparin when included in medicines for external use x PM PM Prescription Only 4.8 Anticonvulsants PM PM Prescription Only 4.3 Ant. id epressants PM PM Prescription Only 2. 11 Antifibrinolytic Prescription Only 3.4 Antigens, in a rnultipuncture device for cutaneous application PCM PM Prescription Only 6.5 Antigonadotrophics Prescription Only - Page 10 - EXTERNAL CURRENT PROPOSED MCC BNF NO MEDICINE USE (X) CLASSIFICATION CLASSIFICATION RECOMMENDATION 3. 4 Antihistamines, except: a) Those specified elsewhere in this Schedule b) Tablets of dimenhydrinate and tablets of promethazine theoclate and tablets of meclozine if sold: i) in a sealed container containing not more than 10 tablets and labelled with or accompanied by printed directions for use for the prevention or alleviation of travel sickness; and ii) at an airport, railway station, bus station or wharf, or in an aircraft or a ship POM PTOM Part II Pharmacy 2.5 Antihypertensives PM PM Prescription Only 5. 1 Antileprotics PM PM Prescription Only 5.4 Antimalarials PM PM Prescription Only .;..;..- 5.0 Antimicrobial medicines being: a) Substances produced by bacteria, fungi, protozoa or viruses; or b) Substances the chemical properties of which are identical with or similar to, any substance within paragraph a) above; or c) Salts of derivatives of substances within paragraph a) or paragraph b) above; except those specified elsewhere in this schedule PM PM Prescription Only - Page 11 - EXTERNAL CURRENT PROPOSED MCC BNF NO MEDICINE USE (X) CLASSIFICATION CLASSIFICATION RECOMMENDATION 8.1 Antimitotics PM PM Prescription Only 3.9 Antimony; and its compounds RM PM Prescription Only • 8.0 Antineoplastics PM PM Prescription Only ..., 6.5 Antioestrogens Prescription Only 4.9 Antiparkinsonians PM PM Prescription Only 4. 2 Antipsychotics PM PM Prescription Only 10. 2 Antispastics Prescription Only 5. 1 Antituberculotics PM PM Prescription Only 4.7 Apomorphine; and its salts RM/POM PM Prescription Only 4. 1 Apronal PM PM Obsolete 2. 11 Aprotinin PM PM Prescription Only 5.5 Arecoline; and its salts PM PM Prescription Only 4.7 Aristolochic acid; and herbal extracts derived from plants of the Aristolochiaceae family, except homoeopathic remedies PM PM Prescription Only 4.7 Aspirin, except in enteric coated and slow release forms G General - Page 12 - EXTERNAL CURRENT PROPOSED MCC BNF NO MEDICINE USE (X) CLASSIFICATION CLASSIFICATION RECOMMENDATION 4. 7 Aspirin, in enteric-coated and slow­ release forms POM PTOM Part I Pharmacy 3.4 Astemizole POM G Part II Pharmacy 2.4 Atenolol PM PM Prescription Only 15. 1 Atracurium; and its salts PM PM Prescription Only 1. 2 -Atropine; and its salts; in medicines containing not more than 0.15% of atropine; or in injectable form for use as an antidote; and except when sold by licensees under the Toxic Substances Regulations POM G Part II Pharmacy 1.
Load more

Recommended publications
  • Multi-Drug Rapid Test Panel with Adulteration (Urine)
    6-mono-aceto-morphine in urine is 3-7 days. Multi-Drug Rapid Test Panel with 6-MAM 10 Adulteration (Urine) (6-MAM10) The Multi-Drug Rapid Test Panel yields a positive result when the concentration of (±) 3,4-Methylenedioxy- (±) 3,4-Methylenedioxy- benzodiazepines in urine exceeds detective level. Package Insert 500 Buprenorphine (BUP) Amphetamine(MDA500) Amphetamine Instruction Sheet for testing of any combination of the following drugs: Ethyl- β-D-Glucuronide(ETG500) Ethyl- β -D-Glucuronide 500 Buprenorphine is a potent analgesic often used in the treatment of opioid addiction. The drug is ACE/AMP/BAR/BZO/BUP/COC/THC/MTD/MET/MDMA/MOP/MQL/OPI/PCP/PPX/TCA/TML/K sold under the trade names Subutex™, Buprenex™, Temgesic™ and Suboxone™, which ET/OXY/COT/EDDP/FYL/K2/6-MAM/MDA/ETG/CLO/LSD/MPD/ZOL Ethyl- β-D-Glucuronide(ETG1,000) Ethyl- β -D-Glucuronide 1,000 contain Buprenorphine HCl alone or in combination with Naloxone HCl. Therapeutically, Including Specimen Validity Tests (S.V.T.) for: Clonazepam(CLO 400) Clonazepam 400 Buprenorphine is used as a substitution treatment for opioid addicts. Substitution treatment is a Oxidants/PCC, Specific Gravity, pH, Nitrite, Glutaraldehyde and Creatinine Clonazepam(CLO 150) Clonazepam 150 form of medical care offered to opiate addicts (primarily heroin addicts) based on a similar or A rapid test for the simultaneous, qualitative detection of multiple drugs and drug metabolites in identical substance to the drug normally used. In substitution therapy, Buprenorphine is as human urine. For healthcare professionals including professionals at point of care sites. Lysergic Acid Diethylamide (LSD) Lysergic Acid Diethylamide 20 effective as Methadone but demonstrates a lower level of physical dependence.
    [Show full text]
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group R01 (Nasal preparations) Table of Contents Page INTRODUCTION 5 DISCLAIMER 7 GLOSSARY OF TERMS USED IN THIS DOCUMENT 8 ACTIVE SUBSTANCES Cyclopentamine (ATC: R01AA02) 10 Ephedrine (ATC: R01AA03) 11 Phenylephrine (ATC: R01AA04) 14 Oxymetazoline (ATC: R01AA05) 16 Tetryzoline (ATC: R01AA06) 19 Xylometazoline (ATC: R01AA07) 20 Naphazoline (ATC: R01AA08) 23 Tramazoline (ATC: R01AA09) 26 Metizoline (ATC: R01AA10) 29 Tuaminoheptane (ATC: R01AA11) 30 Fenoxazoline (ATC: R01AA12) 31 Tymazoline (ATC: R01AA13) 32 Epinephrine (ATC: R01AA14) 33 Indanazoline (ATC: R01AA15) 34 Phenylephrine (ATC: R01AB01) 35 Naphazoline (ATC: R01AB02) 37 Tetryzoline (ATC: R01AB03) 39 Ephedrine (ATC: R01AB05) 40 Xylometazoline (ATC: R01AB06) 41 Oxymetazoline (ATC: R01AB07) 45 Tuaminoheptane (ATC: R01AB08) 46 Cromoglicic Acid (ATC: R01AC01) 49 2 Levocabastine (ATC: R01AC02) 51 Azelastine (ATC: R01AC03) 53 Antazoline (ATC: R01AC04) 56 Spaglumic Acid (ATC: R01AC05) 57 Thonzylamine (ATC: R01AC06) 58 Nedocromil (ATC: R01AC07) 59 Olopatadine (ATC: R01AC08) 60 Cromoglicic Acid, Combinations (ATC: R01AC51) 61 Beclometasone (ATC: R01AD01) 62 Prednisolone (ATC: R01AD02) 66 Dexamethasone (ATC: R01AD03) 67 Flunisolide (ATC: R01AD04) 68 Budesonide (ATC: R01AD05) 69 Betamethasone (ATC: R01AD06) 72 Tixocortol (ATC: R01AD07) 73 Fluticasone (ATC: R01AD08) 74 Mometasone (ATC: R01AD09) 78 Triamcinolone (ATC: R01AD11) 82
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2005/0129775 A1 Lanphere Et Al
    US 2005O129775A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2005/0129775 A1 Lanphere et al. (43) Pub. Date: Jun. 16, 2005 (54) FERROMAGNETIC PARTICLES AND (22) Filed: Aug. 27, 2004 METHODS Related U.S. Application Data (75) Inventors: Janel Lanphere, Pawtucket, RI (US); Erin McKenna, Boston, MA (US); (63) Continuation-in-part of application No. 10/651,475, Thomas V. Casey II, Grafton, MA filed on Aug. 29, 2003. (US) Publication Classification Correspondence Address: FISH & RICHARDSON PC (51) Int. Cl." ........................... A61K 9/127; A61K 9/14; 225 FRANKLIN ST A61K 33/26 BOSTON, MA 02110 (US) (52) U.S. Cl. ............................................ 424/489; 424/646 (73) ASSignee: Siedle Systems, Inc., Maple (57) ABSTRACT (21) Appl. No.: 10/928,452 Ferromagnetic particles and methods are disclosed. Patent Application Publication Jun. 16, 2005 Sheet 1 of 5 US 2005/0129775 A1 Patent Application Publication Jun. 16, 2005 Sheet 2 of 5 US 2005/0129775 A1 s nS) l r N. 1 Yn ESDNIAJ?SdWßd N-EZT| 1 - - - - - - - - - - - - - - - - - - - - - - - - - a - - a - - - - Patent Application Publication Jun. 16, 2005 Sheet 3 of 5 US 2005/0129775 A1 : 3 L D Cl U c). Z Y X C) Patent Application Publication Jun. 16, 2005 Sheet 4 of 5 US 2005/0129775 A1 s s Patent Application Publication Jun. 16, 2005 Sheet 5 of 5 US 2005/0129775 A1 26SS EMBOLIC PARTICLES FIBROID jS. 111 UTERINE ARTERY CATHETER 150 FIG. R., US 2005/0129775 A1 Jun. 16, 2005 FERROMAGNETIC PARTICLES AND METHODS 0011 Heating a particle can include exposing the particle to RF radiation. CROSS-REFERENCE TO RELATED 0012.
    [Show full text]
  • Epinephrine Versus Tramazoline to Reduce Nasal Bleeding During Nasotracheal Intubation. a Double- Blind Randomized Trial
    Epinephrine versus tramazoline to reduce nasal bleeding during nasotracheal intubation. A double- blind randomized trial Aiji Sato(Boku) ( [email protected] ) Aichi Gakuin University Yoshiki Sento Nagoya City University Yuji Kamimura Nagoya City University Eisuke Kako Nagoya City University Masahiro Okuda Aichi Gakuin University Naoko Tachi Aichi Gakuin University Yoko Okumura Aichi Gakuin University Mayumi Hashimoto Aichi Gakuin University Hiroshi Hoshijima Tohoku University Fumihito Suzuki Akita National Hospital Kazuya Sobue Nagoya City University Research Article Keywords: Nasotracheal intubation, Epinephrine, Tramazoline, Nasal bleeding Posted Date: February 10th, 2021 DOI: https://doi.org/10.21203/rs.3.rs-148779/v1 Page 1/14 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 2/14 Abstract BACKGROUND Nasal bleeding is the most common complication during nasotracheal intubation (NTI). To reduce nasal bleeding, the nasal cavity is treated with vasoconstrictors (epinephrine [E] or tramazoline [T]) prior to NTI. This study aimed to determine whether E or T is more effective and safe for reducing nasal bleeding during NTI. METHODS This study was preregistered on UMIN-CTR after being approved by the IRB of the School of Dentistry at Aichi Gakuin University. Written consent was received from all the patients. Total 206 patients aged 20–70 years and classied as 1–2 on American Society of Anesthesiologists-physical status were scheduled to undergo general anesthesia with NTI. Patients with a narrowed nasal cavity observed during preoperative CT test (n = 3), patients with hypertension (n = 3), patients undergoing antithrombotic therapy, and patients who did not give consent (n = 3) were excluded from the study.
    [Show full text]
  • List of Union Reference Dates A
    Active substance name (INN) EU DLP BfArM / BAH DLP yearly PSUR 6-month-PSUR yearly PSUR bis DLP (List of Union PSUR Submission Reference Dates and Frequency (List of Union Frequency of Reference Dates and submission of Periodic Frequency of submission of Safety Update Reports, Periodic Safety Update 30 Nov. 2012) Reports, 30 Nov.
    [Show full text]
  • Us Anti-Doping Agency
    2019U.S. ANTI-DOPING AGENCY WALLET CARDEXAMPLES OF PROHIBITED AND PERMITTED SUBSTANCES AND METHODS Effective Jan. 1 – Dec. 31, 2019 CATEGORIES OF SUBSTANCES PROHIBITED AT ALL TIMES (IN AND OUT-OF-COMPETITION) • Non-Approved Substances: investigational drugs and pharmaceuticals with no approval by a governmental regulatory health authority for human therapeutic use. • Anabolic Agents: androstenediol, androstenedione, bolasterone, boldenone, clenbuterol, danazol, desoxymethyltestosterone (madol), dehydrochlormethyltestosterone (DHCMT), Prasterone (dehydroepiandrosterone, DHEA , Intrarosa) and its prohormones, drostanolone, epitestosterone, methasterone, methyl-1-testosterone, methyltestosterone (Covaryx, EEMT, Est Estrogens-methyltest DS, Methitest), nandrolone, oxandrolone, prostanozol, Selective Androgen Receptor Modulators (enobosarm, (ostarine, MK-2866), andarine, LGD-4033, RAD-140). stanozolol, testosterone and its metabolites or isomers (Androgel), THG, tibolone, trenbolone, zeranol, zilpaterol, and similar substances. • Beta-2 Agonists: All selective and non-selective beta-2 agonists, including all optical isomers, are prohibited. Most inhaled beta-2 agonists are prohibited, including arformoterol (Brovana), fenoterol, higenamine (norcoclaurine, Tinospora crispa), indacaterol (Arcapta), levalbuterol (Xopenex), metaproternol (Alupent), orciprenaline, olodaterol (Striverdi), pirbuterol (Maxair), terbutaline (Brethaire), vilanterol (Breo). The only exceptions are albuterol, formoterol, and salmeterol by a metered-dose inhaler when used
    [Show full text]
  • ADD/ADHD: Strattera • Allergy/Anti-Inflammatories
    EXAMPLES OF PERMITTED MEDICATIONS - 2015 ADD/ADHD: Strattera Allergy/Anti-Inflammatories: Corticosteroids, including Decadron, Depo-Medrol, Entocort, Solu-Medrol, Prednisone, Prednisolone, and Methylprednisolone Anesthetics: Alcaine, Articadent, Bupivacaine HCI, Chloroprocaine, Citanest Plain Dental, Itch-X, Lidocaine, Marcaine, Mepivacaine HCI, Naropin, Nesacaine, Novacain, Ophthetic, Oraqix, Paracaine, Polocaine, Pontocaine Hydrochloride, PrameGel, Prax, Proparacaine HCI, Ropivacaine, Sarna Ultra, Sensorcaine, Synera, Tetracaine, Tronothane HCI, and Xylocaine Antacids: Calci-Chew, Di-Gel, Gaviscon, Gelusil, Maalox, Mintox Plus, Mylanta, Oyst-Cal 500, Rolaids, and Tums Anti-Anxiety: Alprazolam, Atarax, Ativan, Buspar, Buspirone HCI, Chlordiazepoxide HCI, Clonazepam, Chlorazepate Dipotassium, Diastat, Diazepam, Hydroxyzine, Klonopin, Librium, Lorazepam, Niravam, Tranxene T-tab, Valium, Vistaril, and Xanax Antibiotics: Acetasol HC, Amoxil, Ampicillin, Antiben, Antibiotic-Cort, Antihist, Antituss, Avelox, Ceftazidime, Ceftin, Cefuroxime Axetil, Ceptaz, Cleocin, Cloxapen, Cortane-B Aqueous, Cortic, Cresylate, Debrox, Doryx, EarSol-HC, Fortaz, Gantrisin, Mezlin, Moxifloxacin, Neotic, Otocain, Principen, Tazicef, Tazidime, Trioxin, and Zyvox Anti-Depressants: Adapin, Anafranil, Asendin, Bolvidon, Celexa, Cymbalata, Deprilept, Effexor, Elavil, Lexapro, Luvox, Norpramin, Pamelor, Paxil, Pristiq, Prozac, Savella, Surmontil, Tofranil, Vivactil, Wellbutrin, Zoloft, and Zyban Anti-Diabetics: Actos, Amaryl, Avandia, Glipizide, Glucophage,
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • Supplementary Materials 07/09/2017
    SMART Adolescent manuscript: Supplementary materials 07/09/2017 Supplementary materials Methods Definition and calculation of severe exacerbations The first three studies conducted 10-12, defined severe exacerbations as the need for oral corticosteroid (OCS) and/or hospitalisation/emergency room care due to asthma and/or a decrease in peak expiratory flow (PEF) of ≥30% on two consecutive days compared with the run-in period. In these studies, exacerbations were to be treated with a 10-day OCS course; an exacerbation lasting >10 days was considered a new exacerbation on the 11th day. Based on this experience, the later three studies 13-15 did not include falls in PEF in the exacerbation definition, nor this stipulated OCS treatment time, defining a severe exacerbation as the need for OCS for ≥3 days and/or hospitalisation/emergency room care due to asthma worsening. For the purpose of this analysis, we defined a severe exacerbation as the need for OCS (for ≥3 days 10-12) and/or hospitalisation/emergency room care due to asthma worsening; to align with this definition, data from 3 of the included studies 13-15 were reanalysed to exclude PEF fall from the exacerbation definition. 1 SMART Adolescent manuscript: Supplementary materials 07/09/2017 Literature review to identify any additional studies We conducted a review to identify any additional randomised controlled trials (RCTs) evaluating a combination of inhaled corticosteroids (ICS) and a rapid- acting bronchodilator in a single inhaler for both maintenance and as-needed relief of symptoms
    [Show full text]
  • Uniform Classification Guidelines for Foreign Substances and Recommended Penalties Model Rule
    DRUG TESTING STANDARDS AND PRACTICES PROGRAM. Uniform Classification Guidelines for Foreign Substances And Recommended Penalties Model Rule. January, 2018 (V.13.4) Ó ASSOCIATION OF RACING COMMISSIONERS INTERNATIONAL – 2018. Association of Racing Commissioners International 1510 Newtown Pike, Lexington, Kentucky, United States www.arci.com Page 1 of 61 Preamble to the Uniform Classification Guidelines of Foreign Substances The Preamble to the Uniform Classification Guidelines was approved by the RCI Drug Testing and Quality Assurance Program Committee (now the Drug Testing Standards and Practices Program Committee) on August 26, 1991. Minor revisions to the Preamble were made by the Drug Classification subcommittee (now the Veterinary Pharmacologists Subcommittee) on September 3, 1991. "The Uniform Classification Guidelines printed on the following pages are intended to assist stewards, hearing officers and racing commissioners in evaluating the seriousness of alleged violations of medication and prohibited substance rules in racing jurisdictions. Practicing equine veterinarians, state veterinarians, and equine pharmacologists are available and should be consulted to explain the pharmacological effects of the drugs listed in each class prior to any decisions with respect to penalities to be imposed. The ranking of drugs is based on their pharmacology, their ability to influence the outcome of a race, whether or not they have legitimate therapeutic uses in the racing horse, or other evidence that they may be used improperly. These classes of drugs are intended only as guidelines and should be employed only to assist persons adjudicating facts and opinions in understanding the seriousness of the alleged offenses. The facts of each case are always different and there may be mitigating circumstances which should always be considered.
    [Show full text]
  • THC Exchange
    QUALIFIED HEALTH PLAN FORMULARY Effective July 2015 Provided by EnvisionRxOptions Introduction The Total Health Care (THC) Qualified Health Plan Formulary was developed to serve as a guide for physicians, pharmacists, health care professionals and members in the selection of cost-effective drug therapy. Total Health Care recognizes that drug therapy is an integral part of effective health management. Total Health Care continually reviews new and existing medications to ensure the Formulary remains responsive to the needs of our members and health professionals. Criteria used to evaluate drug selection for the formulary includes, but is not limited to: safety, efficacy and cost-effectiveness data, as well as comparison of relevant benefits of similar prescription or over-the counter (OTC) agents while minimizing potential duplications. Notice The information contained in this formulary is provided by THC & EnvisionRxOptions, solely for the convenience of medical providers and members. THC does not warrant or assure accuracy of this information, nor is it intended to be comprehensive in nature. This formulary is not intended to be a substitute for the knowledge, expertise, skill or judgment of the medical provider in their choice of prescription drugs. Total Health Care assumes no responsibility for the actions or omissions of any medical provider based upon reliance, in whole or in part, on the information contained herein. The medical provider should consult the drug manufacturer’s product literature or standard references for more detailed information. How to Read the Formulary All formulary drugs are listed either by their generic names (in lowercase) or by their brand names (in uppercase). Drugs are grouped together by their therapeutic drug category.
    [Show full text]
  • The Organic Chemistry of Drug Synthesis
    The Organic Chemistry of Drug Synthesis VOLUME 2 DANIEL LEDNICER Mead Johnson and Company Evansville, Indiana LESTER A. MITSCHER The University of Kansas School of Pharmacy Department of Medicinal Chemistry Lawrence, Kansas A WILEY-INTERSCIENCE PUBLICATION JOHN WILEY AND SONS, New York • Chichester • Brisbane • Toronto Copyright © 1980 by John Wiley & Sons, Inc. All rights reserved. Published simultaneously in Canada. Reproduction or translation of any part of this work beyond that permitted by Sections 107 or 108 of the 1976 United States Copyright Act without the permission of the copyright owner is unlawful. Requests for permission or further information should be addressed to the Permissions Department, John Wiley & Sons, Inc. Library of Congress Cataloging in Publication Data: Lednicer, Daniel, 1929- The organic chemistry of drug synthesis. "A Wiley-lnterscience publication." 1. Chemistry, Medical and pharmaceutical. 2. Drugs. 3. Chemistry, Organic. I. Mitscher, Lester A., joint author. II. Title. RS421 .L423 615M 91 76-28387 ISBN 0-471-04392-3 Printed in the United States of America 10 987654321 It is our pleasure again to dedicate a book to our helpmeets: Beryle and Betty. "Has it ever occurred to you that medicinal chemists are just like compulsive gamblers: the next compound will be the real winner." R. L. Clark at the 16th National Medicinal Chemistry Symposium, June, 1978. vii Preface The reception accorded "Organic Chemistry of Drug Synthesis11 seems to us to indicate widespread interest in the organic chemistry involved in the search for new pharmaceutical agents. We are only too aware of the fact that the book deals with a limited segment of the field; the earlier volume cannot be considered either comprehensive or completely up to date.
    [Show full text]